VR Adviser »

Jade Biosciences shares owned by VR Adviser

Quarter-by-quarter ownership of Jade Biosciences (JBIO) shares owned by VR Adviser from 13F filings

Historical chart of VR Adviser investment in Jade Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Jade Biosciences held by VR Adviser consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Jade Biosciences by VR Adviser

Quarter filed Position value Share count Share price at filing
2025-09-30 $28M 3.2M 8.63
2025-06-30 $32M 3.2M 9.99

More positions owned by VR Adviser

Apogee Therapeutics (APGE)
Mestera (MTSR)
Ocular Therapeutix (OCUL)
Cidara Therapeutics Com New (CDTX)
Miragen Therapeutics (VRDN)
Kalvista Pharmaceuticals (KALV)
Oruka Therapeutics (ORKA)
Oric Pharmaceuticals (ORIC)
Enliven Therapeutics (ELVN)
Cogent Biosciences (COGT)
Cytomx Therapeutics (CTMX)
Abivax Sa Sponsored Ads (ABVX)
Savara (SVRA)
Spyre Therapeutics Com New (SYRE)
Erasca (ERAS)

View all positions for VR Adviser

Top funds holding Jade Biosciences

FMR
Fairmount Funds Management
VR Adviser
Deep Track Capital
BlackRock
Vanguard Group
Versant Venture Management
Rtw Investments
Frazier Life Sciences Management
Driehaus Capital Management
Avidity Partners Management
RA Capital Management
Soleus Capital Management
Geode Capital Management
Dr. Jeffrey R. Jay, M.D.

View all funds holding Jade Biosciences